Smalley KSM - Search Results

1

Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases.

Smalley I, Chen Z, Phadke M, Li J, Yu X, Wyatt C, Evernden B, Messina JL, Sarnaik A, Sondak VK, Zhang C, Law V, Tran N, Etame A, Macaulay RJB, Eroglu Z, Forsyth PA, Rodriguez PC, Chen YA, Smalley KSM. Smalley I, et al. Among authors: smalley ksm. Clin Cancer Res. 2021 Jul 15;27(14):4109-4125. doi: 10.1158/1078-0432.CCR-21-1694. Epub 2021 May 25. Clin Cancer Res. 2021. PMID: 34035069 Free PMC article.

2

Integrating tumor-initiating cells into the paradigm for melanoma targeted therapy.

Smalley KS, Herlyn M. Smalley KS, et al. Int J Cancer. 2009 Mar 15;124(6):1245-50. doi: 10.1002/ijc.24129. Int J Cancer. 2009. PMID: 19089923 Free article. Review.

3

c-KIT signaling as the driving oncogenic event in sub-groups of melanomas.

Smalley KS, Sondak VK, Weber JS. Smalley KS, et al. Histol Histopathol. 2009 May;24(5):643-50. doi: 10.14670/HH-24.643. Histol Histopathol. 2009. PMID: 19283671 Review.

4

Understanding melanoma signaling networks as the basis for molecular targeted therapy.

Smalley KS. Smalley KS. J Invest Dermatol. 2010 Jan;130(1):28-37. doi: 10.1038/jid.2009.177. J Invest Dermatol. 2010. PMID: 19571822 Free article.

5

Targeting mutant BRAF and KIT in metastatic melanoma: ASCO 2009 meeting report.

Sondak VK, Smalley K. Sondak VK, et al. Pigment Cell Melanoma Res. 2009 Aug;22(4):386-7. doi: 10.1111/j.1755-148X.2009.00593.x. Pigment Cell Melanoma Res. 2009. PMID: 19624312 No abstract available.

6

Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.

Paraiso KH, Fedorenko IV, Cantini LP, Munko AC, Hall M, Sondak VK, Messina JL, Flaherty KT, Smalley KS. Paraiso KH, et al. Br J Cancer. 2010 Jun 8;102(12):1724-30. doi: 10.1038/sj.bjc.6605714. Br J Cancer. 2010. PMID: 20531415 Free PMC article.

7

Melanoma--an unlikely poster child for personalized cancer therapy.

Smalley KS, Sondak VK. Smalley KS, et al. N Engl J Med. 2010 Aug 26;363(9):876-8. doi: 10.1056/NEJMe1005370. N Engl J Med. 2010. PMID: 20818849 No abstract available.

8

Measurement of constitutive MAPK and PI3K/AKT signaling activity in human cancer cell lines.

Paraiso KH, Van Der Kooi K, Messina JL, Smalley KS. Paraiso KH, et al. Methods Enzymol. 2010;484:549-67. doi: 10.1016/B978-0-12-381298-8.00027-7. Methods Enzymol. 2010. PMID: 21036250 Free PMC article.

9

PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression.

Paraiso KH, Xiang Y, Rebecca VW, Abel EV, Chen YA, Munko AC, Wood E, Fedorenko IV, Sondak VK, Anderson AR, Ribas A, Palma MD, Nathanson KL, Koomen JM, Messina JL, Smalley KS. Paraiso KH, et al. Cancer Res. 2011 Apr 1;71(7):2750-60. doi: 10.1158/0008-5472.CAN-10-2954. Epub 2011 Feb 11. Cancer Res. 2011. PMID: 21317224 Free PMC article.

10

Ipilimumab.

Sondak VK, Smalley KS, Kudchadkar R, Grippon S, Kirkpatrick P. Sondak VK, et al. Nat Rev Drug Discov. 2011 Jun;10(6):411-2. doi: 10.1038/nrd3463. Nat Rev Drug Discov. 2011. PMID: 21629286 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

198 results

Search Page